GLP-1 medications have transformed the conversation around obesity, appetite control, and metabolic health. Drugs like semaglutide and tirzepatide have demonstrated that helping people feel fuller can lead to substantial improvements in body weight and blood sugar regulation.
But what if GLP-1 isn’t the only hormone responsible for these effects?
In this week’s Metabolic Classroom, I explore a lesser-known hormone called amylin—a natural partner of insulin that is quickly becoming one of the most exciting targets in obesity and diabetes research.
Prefer to listen without the ads? Become a Ben Bikman Insider.
What Is Amylin?
Every time your pancreas releases insulin, it also releases amylin.
While insulin helps move nutrients into tissues, amylin performs a very different role. It helps regulate appetite, digestion, and blood sugar by:
- Increasing feelings of fullness
- Slowing stomach emptying
- Reducing inappropriate glucagon release after meals
- Helping control blood sugar without requiring more insulin
In many ways, amylin acts as an “insulin-sparing” hormone. Rather than forcing the body to produce more insulin, it helps reduce the glucose burden that the body must manage in the first place.
Why Amylin Matters
One of the most fascinating aspects of amylin is that it is produced by the same pancreatic beta cells that make insulin.
As beta cell function declines—as occurs in type 1 diabetes and later stages of type 2 diabetes—amylin production declines as well.
This means that many people struggling with appetite regulation, blood sugar control, and metabolic dysfunction may also be missing an important satiety signal that their bodies once produced naturally.
Researchers began asking a simple question:
What happens if we replace it?
The Challenge of Turning Amylin Into a Drug
Unfortunately, natural human amylin has a major flaw.
It tends to clump together and form structures known as amyloid deposits. These deposits are commonly found in the pancreas of people with type 2 diabetes and may contribute to the gradual decline in beta cell function over time.
Because of this tendency, natural amylin is difficult to use as a medication.
Scientists eventually solved the problem through protein engineering, creating modified versions of amylin that retain its beneficial effects while avoiding the tendency to form harmful amyloid aggregates.
This breakthrough paved the way for an entirely new category of metabolic therapies.
Why Drug Developers Are Pairing Amylin With GLP-1
The most exciting development isn’t amylin alone—it’s amylin combined with GLP-1.
Although both hormones help reduce appetite, they communicate with the brain through different pathways. Rather than simply duplicating one another’s effects, they appear to complement each other.
This complementary biology is what makes the combination so compelling.
Researchers have also discovered that amylin may help restore the brain’s sensitivity to leptin, another hormone involved in long-term appetite regulation. Because leptin resistance is common in obesity, improving leptin signaling could further enhance weight-loss outcomes.
Together, these mechanisms may help explain why combining amylin with GLP-1 has produced such impressive results in clinical trials.
The Rise of Next-Generation Weight-Loss Drugs
New medications that combine GLP-1 and amylin activity are already producing remarkable results.
One example is CagriSema, a combination of semaglutide and a long-acting amylin analog called cagrilintide. Clinical trials have demonstrated weight-loss results that exceed what either hormone can achieve alone.
Researchers are also developing entirely new molecules, such as amycretin, that combine both hormone signals into a single medication.
While these therapies are still being studied, they represent an important shift in how scientists think about obesity treatment—not by forcing the body harder, but by restoring multiple natural signals that regulate hunger and fullness.
A Different Approach to Metabolic Health
What makes the amylin story so interesting is that it highlights a broader principle of metabolic health.
The body’s appetite and energy balance systems are controlled by a network of hormones that work together. When one signal becomes impaired, restoring that signal—or combining multiple signals—may produce far better results than focusing on a single pathway alone.
Amylin may have spent decades living in insulin’s shadow, but it is rapidly becoming one of the most important hormones in modern metabolic medicine.
And as researchers continue to explore how amylin works alongside GLP-1 and other metabolic signals, it may help define the next generation of therapies for obesity, diabetes, and metabolic disease.
Watch the full Metabolic Classroom episode above to learn more about the science of amylin and why researchers believe it may be one of the most promising advances in metabolic health.